Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Search Results
8 results
Filters applied: . Clear all
Results are displayed in a computed author sort order.
The Results By Year timeline is not available.
Page 1
Thiosemicarbazone Derivatives Developed to Overcome COTI-2 Resistance.
Cancers (Basel). 2022 Sep 14;14(18):4455. doi: 10.3390/cancers14184455.
Cancers (Basel). 2022.
PMID: 36139615
Free PMC article.
Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib.
Karnthaler-Benbakka C, Koblmüller B, Mathuber M, Holste K, Berger W, Heffeter P, Kowol CR, Keppler BK.
Karnthaler-Benbakka C, et al. Among authors: mathuber m.
Chem Biodivers. 2019 Jan;16(1):e1800520. doi: 10.1002/cbdv.201800520. Epub 2018 Dec 19.
Chem Biodivers. 2019.
PMID: 30566287
Free PMC article.
Item in Clipboard
Cancer Cell Resistance Against the Clinically Investigated Thiosemicarbazone COTI-2 Is Based on Formation of Intracellular Copper Complex Glutathione Adducts and ABCC1-Mediated Efflux.
Bormio Nunes JH, Hager S, Mathuber M, Pósa V, Roller A, Enyedy ÉA, Stefanelli A, Berger W, Keppler BK, Heffeter P, Kowol CR.
Bormio Nunes JH, et al. Among authors: mathuber m.
J Med Chem. 2020 Nov 25;63(22):13719-13732. doi: 10.1021/acs.jmedchem.0c01277. Epub 2020 Nov 15.
J Med Chem. 2020.
PMID: 33190481
Free PMC article.
Item in Clipboard
Improving the Stability of EGFR Inhibitor Cobalt(III) Prodrugs.
Mathuber M, Schueffl H, Dömötör O, Karnthaler C, Enyedy ÉA, Heffeter P, Keppler BK, Kowol CR.
Mathuber M, et al.
Inorg Chem. 2020 Dec 7;59(23):17794-17810. doi: 10.1021/acs.inorgchem.0c03083. Epub 2020 Nov 21.
Inorg Chem. 2020.
PMID: 33222438
Free PMC article.
Item in Clipboard
Development of a cobalt(iii)-based ponatinib prodrug system.
Mathuber M, Gutmann M, La Franca M, Vician P, Laemmerer A, Moser P, Keppler BK, Berger W, Kowol CR.
Mathuber M, et al.
Inorg Chem Front. 2021 Mar 30;8(10):2468-2485. doi: 10.1039/d1qi00211b.
Inorg Chem Front. 2021.
PMID: 34046181
Free PMC article.
Item in Clipboard
Liposomal formulations of anticancer copper(II) thiosemicarbazone complexes.
Mathuber M, Hager S, Keppler BK, Heffeter P, Kowol CR.
Mathuber M, et al.
Dalton Trans. 2021 Nov 16;50(44):16053-16066. doi: 10.1039/d1dt02763h.
Dalton Trans. 2021.
PMID: 34617075
Free PMC article.
Item in Clipboard
A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo.
Caban M, Koblmueller B, Groza D, Schueffl HH, Terenzi A, Tolios A, Mohr T, Mathuber M, Kryeziu K, Jaunecker C, Pirker C, Keppler BK, Berger W, Kowol CR, Heffeter P.
Caban M, et al. Among authors: mathuber m.
Cancer Lett. 2023 Jul 1;565:216237. doi: 10.1016/j.canlet.2023.216237. Epub 2023 May 19.
Cancer Lett. 2023.
PMID: 37211067
Free article.
Item in Clipboard
In vitro biodistribution studies on clinically approved FGFR inhibitors ponatinib, nintedanib, erlotinib and the investigational inhibitor KP2692.
Dömötör O, Mathuber M, Kowol CR.
Dömötör O, et al. Among authors: mathuber m.
Eur J Pharm Sci. 2024 Jan 1;192:106651. doi: 10.1016/j.ejps.2023.106651. Epub 2023 Nov 25.
Eur J Pharm Sci. 2024.
PMID: 38013124
Free article.
Item in Clipboard
Cite
Cite